| Type | Title | Date Released | |
|---|---|---|---|
25-NSE | Form 25-NSE | ||
8-K | Biofrontera Announces FDA Approval of Ameluz ® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma | ||
10-Q | Form 10-Q | ||
8-K | Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth | ||
SCHEDULE 13G/A | Rosalind Advisors, Inc. (Filed by) | ||
4 | Luebbert Hermann (Reporting) | ||
4 | Leffler Eugene Frederick (Reporting) | ||
S-8 | Form S-8 | ||
10-K/A | Form 10-K/A | ||
8-K | Biofrontera Inc. Announces Results of 2026 Annual Meeting of Stockholders | ||
10-Q | Form 10-Q | ||
8-K | Biofrontera Inc. Reports First Quarter 2026 Financial Results and Business Update |
